Share ownership Eisai Co., Ltd.

4523

JP3160400002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 12:00:00 12/06/2026 pm IST			5-day change	1st Jan Change
3,780.00 ^JPY	+1.53%		+0.13%	-18.88%

11/06	Beren Therapeutics P.B.C. announced that it has received $245 million in funding from Eisai Co., Ltd., The Founders Fund, LLC, Wellington Partners Advisory AG, Narya Capital, JIC Venture Growth Investments Co., Ltd. and other investors	CI
04/06	Eisai Co., Ltd. Announces Issuance of Unsecured Straight Bonds	CI

Share class: Eisai Co., Ltd.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	29,16,49,149	26,46,01,140 ( 90.73 %)	95,35,293 ( 3.269 %)	90.73 %

Major shareholders: Eisai Co., Ltd.

Name	Stocks	%	Valuation
Wellington Management Co. LLP 4.816 %	1,40,44,848	4.816 %	351 M ¥
EISAI CO., LTD. 3.269 %	95,34,400	3.269 %	239 M ¥
Amova Asset Management Co., Ltd. 3.035 %	88,52,300	3.035 %	222 M ¥
Nippon Life Insurance Co. 2.229 %	65,00,000	2.229 %	163 M ¥
BlackRock Fund Advisors 2.108 %	61,48,100	2.108 %	154 M ¥
BlackRock Japan Co. Ltd. 1.917 %	55,91,400	1.917 %	140 M ¥
The Naito Foundation 1.444 %	42,12,000	1.444 %	105 M ¥
BlackRock Financial Management, Inc. 1.175 %	34,26,211	1.175 %	86 M ¥
RESONA HOLDINGS, INC. 0.9601 %	28,00,000	0.9601 %	70 M ¥
BlackRock Investment Management (UK) Ltd. 0.898 %	26,19,154	0.898 %	66 M ¥
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
RhumbLine Advisers LP 0.005338 %	62,274	0.005338 %	389 648 ¥
GAMMA Investing LLC 0.000395 %	4,603	0.000395 %	28 801 ¥
Salomon & Ludwin LLC 0.000198 %	2,315	0.000198 %	14 485 ¥

Breakdown by shareholder type

Institutional	18.19%
Eisai Co., Ltd.	3.27%
Others	1.54%
Resona Holdings, Inc.	0.96%
Tokio Marine Holdings, Inc.	0.59%
MatsukiyoCocokara & Co.	0.28%
MS&AD Insurance Group Holdings, Inc.	0.25%
Medipal Holdings Corp.	0.24%
Individuals	0.23%
Vital KSK Holdings, Inc.	0.09%
Hisamitsu Pharmaceutical Co., Inc.	0.09%
Nihon Kohden Corp.	0.08%
HOKUYAKU TAKEYAMA Holdings, Inc.	0.07%
TAISEI Corp.	0.04%
Marusan Securities Co., Ltd.	0.01%
Taiyo Kagaku Co., Ltd.	0.01%
INTAGE HOLDINGS, Inc.	0.01%
Unknown	74.05%

Based on 1000 largest holdings

Geographical origin of shareholders

Japan	15.15%
United States	8.49%
United Kingdom	1.01%
Canada	0.31%
Netherlands	0.28%
Individuals	0.23%
Sweden	0.15%
Ireland	0.09%
Norway	0.07%
New Zealand	0.03%
Singapore	0.03%
Denmark	0.03%
Australia	0.02%
Luxembourg	0.02%
Finland	0.01%
Switzerland	0.01%
Spain	0.01%
South Africa	0.01%
Germany	0.01%

Based on 1000 largest holdings

Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.

Employees

10,917

Sector

Pharmaceuticals

Calendar

Earnings release - Q1 2027

More about the company